Neptune Technologies & Bioressources Inc. Welcomes Dr. Anthony Holler to Its Board of Directors
July 05 2011 - 7:00AM
Neptune Technologies & Bioressources Inc. (Neptune)
(Nasdaq:NEPT) (TSX-V:NTB) is pleased to announce that Dr. Anthony
Holler, the former CEO of a biomedical company that grew from a
market cap of $25 million to $1.7 billion under his leadership,
will be joining Neptune's board.
Dr. Holler was CEO of ID Biomedical from 1999 until 2005 when
the company was sold to GlaxoSmithKline for $1.7
billion. ID Biomedical was dedicated to the commercial
development of medical products and technologies for the diagnosis,
treatment and prevention of human infectious diseases. Dr.
Holler also sits on numerous corporate boards across the
Country.
"It is with great honour that we welcome Dr. Holler as a member
of our Board of Directors," said Henri Harland, CEO of Neptune
Technologies & Bioressources Inc. "Dr. Holler will bring
new expertise to our Board with his knowledge of the capital
markets as well as the scientific community. His many achievements
speak for themselves," added Mr. Harland.
"It is with great pleasure and anticipation that I have joined
the board of Neptune," said Dr. Holler."My experience in building
ID Biomedical from inception through research and development,
manufacturing and product approval should be very valuable in my
new role as a director of Neptune. I am excited to help in the
building of a very promising enterprise and building shareholder
value," he added.
Neptune granted to Dr. Holler a total of 25,000 stock options
exercisable at $3.50 and expiring on June 28th 2014.
Neptune Technologies & Bioressources
Inc.
Neptune is an industry-recognized leader in the innovation,
production and formulation of science-based and clinically proven
novel phospholipid products for the nutraceutical and
pharmaceutical markets. The Company focuses on growing consumer
health markets including cardiovascular, inflammatory and
neurological diseases driven by consumers taking a more proactive
approach to managing health and preventing disease. The Company
sponsors clinical trials aimed to demonstrate its product health
benefits and to obtain regulatory approval for label health claims.
Neptune is continuously expanding its intellectual property
portfolio as well as clinical studies and regulatory approvals.
Neptune's products are marketed and distributed in over 20
countries worldwide.
About Acasti Pharma Inc.
Acasti Pharma (TSX-V:APO) is developing a product portfolio of
proprietary novel long-chain omega-3 phospholipids. Phospholipids
are the major component of cell membranes and are essential for all
vital cell processes. They are one of the principal constituents of
High Density Lipoprotein (good cholesterol) and, as such, play an
important role in modulating cholesterol efflux. Acasti Pharma's
proprietary novel phospholipids carry and functionalize the
polyunsaturated omega-3 fatty acids EPA and DHA, which have been
shown to have substantial health benefits and which are stabilized
by astaxanthin, a potent antioxidant. Acasti Pharma is focusing
initially on treatments for chronic cardiovascular and
cardiometabolic conditions within the over-the-counter, medical
food and prescription drug markets.
About NeuroBioPharm Inc.
NeuroBioPharm is pursuing pharmaceutical neurological
applications, and a clinical study for a medical food product with
a multinational partner is already initiated. The development of a
prescription drug candidate is currently in progress. Advanced
clinical development and commercialization is planned to be carried
out with multinational partners.
"Neither Nasdaq nor the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release."
Statements in this press release that are not
statements of historical or current fact constitute
"forward-looking statements" within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of the Company to be materially different
from historical results or from any future results expressed or
implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and
uncertainties, readers are urged to consider statements
labeled with the terms "believes," "belief," "expects," "intends,"
"anticipates," "will," or "plans" to be uncertain and
forward-looking. The forward-looking statements contained herein
are also subject generally to other risks and uncertainties that
are described from time to time in the Company's reports filed with
the Securities and Exchange Commission and the Canadian securities
commissions.
CONTACT: Neptune Contact:
Neptune Technologies & Bioressources Inc.
Andre Godin, CFO
+1.450.687.2262
a.godin@neptunebiotech.com
www.neptunebiotech.com
CEOcast Contact:
Dan Schustack
+1 212-732-4300
dschustack@ceocast.com
www.ceocast.com
Howard Group Contact:
Bob Beaty
(888) 221-0915
bob@howardgroupinc.com
www.howardgroupinc.com
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jun 2024 to Jul 2024
New Tymbal Resources (TSXV:NTB)
Historical Stock Chart
From Jul 2023 to Jul 2024